Mahmoud Al-Majdoub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mahmoud Al-Majdoub has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Peter Spégel
Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden
2 shared publications - Bledar Daka
School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
1 shared publication - Katharina Herzog
Centre for Analysis and Synthesis, Department of Chemistry, Lund University, 223 62 Lund, Sweden
1 shared publication - Lennart Råstam
Department of Clinical Sciences in Malmö General Practice, Center for Primary Health Care Research, Lund University, 205 02, Malmö, Sweden
1 shared publication - Martin Magnusson
Department of Clinical Sciences Malmö, Lund University , Malmö
1 shared publication - Mikael Lantz
Department of Endocrinology, Skåne University Hospital, Malmö, Sweden
1 shared publication
Latest Publications
- Open Access
- 15 November 2018
- Published by MDPI AG in Metabolites
- Vol. 8 (4) , 78
Population-Level Analysis to Determine Parameters That Drive Variation in the Plasma Metabolite Profiles
The plasma metabolome is associated with multiple phenotypes and diseases. However, a systematic study investigating clinical determinants that control the metabolome has not yet been conducted. In the present study, therefore, we aimed to identify the major determinants of the plasma metabolite profile. We used ultra-high performance liquid chromatography (UHPLC) coupled to quadrupole time of flight mass spectrometry (QTOF-MS) to determine 106 metabolites in plasma samples from 2503 subjects in a cross-sectional study. We investigated the correlation structure of the metabolite profiles and generated uncorrelated metabolite factors using principal component analysis (PCA) and varimax rotation. Finally, we investigated associations between these factors and 34 clinical covariates. Our results suggest that liver function, followed by kidney function and insulin resistance show the strongest associations with the plasma metabolite profile. The association of specific phenotypes with several components may suggest multiple independent metabolic mechanisms, which is further supported by the composition of the associated factors.
- 15 November 2018
- Published by MDPI AG in Metabolites
- Vol. 8 (4) , 78
Open AccessPopulation-Level Analysis to Determine Parameters That Drive Variation in the Plasma Metabolite Profiles
The plasma metabolome is associated with multiple phenotypes and diseases. However, a systematic study investigating clinical determinants that control the metabolome has not yet been conducted. In the present study, therefore, we aimed to identify the major determinants of the plasma metabolite profile. We used ultra-high performance liquid chromatography (UHPLC) coupled to quadrupole time of flight mass spectrometry (QTOF-MS) to determine 106 metabolites in plasma samples from 2503 subjects in a cross-sectional study. We investigated the correlation structure of the metabolite profiles and generated uncorrelated metabolite factors using principal component analysis (PCA) and varimax rotation. Finally, we investigated associations between these factors and 34 clinical covariates. Our results suggest that liver function, followed by kidney function and insulin resistance show the strongest associations with the plasma metabolite profile. The association of specific phenotypes with several components may suggest multiple independent metabolic mechanisms, which is further supported by the composition of the associated factors.
- 1 September 2017
- Published by SAGE Publications in Thyroid®
- Vol. 27 (9) , 1109-1117
Treatment of Swedish Patients with Graves' Hyperthyroidism Is Associated with Changes in Acylcarnitine Levels
Background Hyperthyroidism is associated with alterations in metabolism that currently are only partially understood. The objective of the study was to investigate changes in metabolism associated with reinstatement of euthyroidism in Swedish patients. Methods We profiled 80 metabolites in plasma from 10 subjects with Graves' disease at baseline and after 9 and 15 month of treatment to reinstate euthyroidism. Thyroid parameters, thyroid stimulating hormone (TSH), TSH receptor antibodies, free T3 and T4 were followed. Main findings were validated in plasma from 20 subjects with Graves' disease at baseline and at 3, 6, and 9 month. The study was conducted at the endocrinological clinic in Malmö, Sweden. Results Euthyriodism was reinstated at 3 month and thyroid status did not change further during the 15 month follow-up. This was paralleled by altered levels of 9 out of 19 detected acylcarnitines (p<0.05 after adjustment for multiple testing). Levels of short-chain acylcarnitines were decreased, levels of intermediate-chain acylcarnitines elevated and long-chain acylcarnitines unaltered. Conclusions Graves' disease and treatment of the disease is associated with pronounced acyl chain-length dependent alterations in acylcarnitine levels. These changes may be impacted by ethnicity and or dietary differences.
- 1 September 2017
- Published by SAGE Publications in Thyroid®
- Vol. 27 (9) , 1109-1117
Treatment of Swedish Patients with Graves' Hyperthyroidism Is Associated with Changes in Acylcarnitine Levels
Background Hyperthyroidism is associated with alterations in metabolism that currently are only partially understood. The objective of the study was to investigate changes in metabolism associated with reinstatement of euthyroidism in Swedish patients. Methods We profiled 80 metabolites in plasma from 10 subjects with Graves' disease at baseline and after 9 and 15 month of treatment to reinstate euthyroidism. Thyroid parameters, thyroid stimulating hormone (TSH), TSH receptor antibodies, free T3 and T4 were followed. Main findings were validated in plasma from 20 subjects with Graves' disease at baseline and at 3, 6, and 9 month. The study was conducted at the endocrinological clinic in Malmö, Sweden. Results Euthyriodism was reinstated at 3 month and thyroid status did not change further during the 15 month follow-up. This was paralleled by altered levels of 9 out of 19 detected acylcarnitines (p<0.05 after adjustment for multiple testing). Levels of short-chain acylcarnitines were decreased, levels of intermediate-chain acylcarnitines elevated and long-chain acylcarnitines unaltered. Conclusions Graves' disease and treatment of the disease is associated with pronounced acyl chain-length dependent alterations in acylcarnitine levels. These changes may be impacted by ethnicity and or dietary differences.